IL-32γ enhances TNF-α-induced cell death in colon cancer

Molecular Carcinogenesis

Volumn 53, Issue S1, 2014, Pages

  Park, Eun Seok ^a   Yoo, Jae Myung ^b   Yoo, Hwan Soo ^c   Yoon, Do Young ^d   Yun, Yeo Pyo ^c   Hong, Jintae ^c  

^a Konkuk University   (South Korea)

^b Chungnam National University   (South Korea)

^c Chungbuk National University   (South Korea)

^d Konkuk University   (South Korea)

Author keywords

Cell death; Colon cancer; Cytokine; Interleukin 32 ; TNF

Indexed keywords

CELL DEATH; COLON CANCER; CYTOKINE; INTERLEUKIN-32Γ; TNF-Α;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894492010     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21990     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Wils J, O'Dwyer P, Labianca R. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol 2001; 12:13-22.
3. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10:45-65.
4. Calzascia T, Pellegrini M, Hall H, et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007; 117:3833-3845.
5. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: A potential target for the therapy of solid tumours. Lancet Oncol 2003; 4:565-573.
6. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-436.
7. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation. Nat Cell Biol 2006; 8:398-406.
8. Han J, Zhong CQ, Zhang DW. Programmed necrosis: Backup to and competitor with apoptosis in the immune system. Nat Immunol 2011; 12:1143-1149.
9. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5:897-907.
10. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87:99-163.
11. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3:221-227.
12. Basu S, Pathak SK, Banerjee A, et al. Execution of macrophage apoptosis by PE_PGRS33 of Mycobacterium tuberculosis is mediated by Toll-like receptor 2-dependent release of tumor necrosis factor-alpha. J Biol Chem 2007; 282:1039-1050.
13. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: Apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18:7719-7730.
14. Hattori T, Hayashi H, Chiba T, Onozaki K. Activation of two distinct anti-proliferative pathways, apoptosis and p38 MAP kinase-dependent cell cycle arrest, by tumor necrosis factor in human melanoma cell line A375. Eur Cytokine Netw 2001; 12:244-252.
15. Lin WW, Karin M. Cytokine-mediated A between link innate immunity inflammation, and cancer. J Clin Invest 2007; 117:1175-1183.
16. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006; 25:387-408.
17. Becker C, Fantini MC, Wirtz S, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005; 4:217-220.
18. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008; 7:2649-2661.
19. Kohno T, Mizukami H, Suzuki M, et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 2003; 63:5091-5094.
20. Chiyo M, Shimozato O, Yu L, et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 2005; 115:437-442.
21. Halin C, Gafner V, Villani ME, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003; 63:3202-3210.
22. Falkensammer C, Johrer K, Gander H, et al. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: Implications for antitumor immune responses. Cancer Immunol Immunother 2006; 55:1228-1237.
23. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: A cytokine and inducer of TNFalpha. Immunity 2005; 22:131-142.
24. Goda C, Kanaji T, Kanaji S, et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 2006; 18:233-240.
25. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 2008; 105:2865-2870.
26. Choi JD, Bae SY, Hong JW, et al. Identification of the most active interleukin-32 isoform. Immunology 2009; 126:535-542.
27. Oh JH, Cho MC, Kim JH, et al. IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene 2011; 30:3345-3359.
28. Wee S, Jagani Z, Xiang KX, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69:4286-4293.
29. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326-1331.
30. McCole DF, Barrett KE. Varied role of the gut epithelium in mucosal homeostasis. Curr Opin Gastroenterol 2007; 23:647-654.
31. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004; 6:297-305.
32. Strassmann G, Fong M, Windsor S, Neta R. The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 1993; 5:285-290.
33. Lasek W, Feleszko W, Golab J, et al. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 1997; 45:100-108.
34. Zhao L, Dong A, Gu J, et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006; 13:1011-1022.
35. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456-1462.
36. Kokura S, Yoshida N, Ishikawa T, et al. Interleukin-10 plasmid DNA inhibits subcutaneous tumor growth of Colon 26 adenocarcinoma in mice. Cancer Lett 2005; 218:171-179.
37. Moon DO, Jin CY, Lee JD, et al. Curcumin decreases binding of Shiga-like toxin-1B on human intestinal epithelial cell line HT29 stimulated with TNF-alpha and IL-1beta: Suppression of p38 JNK and NF-kappaB p65 as potential targets. Biol Pharm Bull 2006; 29:1470-1475.
38. Liu J, Zhao Y, Eilers M, Lin A. Miz1 is a signal- and pathway-specific modulator or regulator (SMOR) that suppresses TNF-alpha-induced JNK1 activation. Proc Natl Acad Sci USA 2009; 106:18279-18284.
39. An MJ, Cheon JH, Kim SW, Kim ES, Kim TI, Kim WH. Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett 2009; 279:93-100.
40. O'Malley WE, Achinstein B, Shear MJ. Action of bacterial polysaccharide on tumors. Iii. Repeated response of sarcoma 37, in tolerant mice, to serratia marcescens endotoxin. Cancer Res 1963; 23:890-895.
41. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666-3670.
42. Suzuki S, Mita S, Kamohara H, Sakamoto K, Ishiko T, Ogawa M. IL-6 and IFN-gamma regulation of IL-10 production by human colon carcinoma cells. Int J Oncol 2001; 18:581-586.
43. Kang JW, Choi SC, Cho MC, et al. A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology 2009; 128:e532-e540.
44. Choi J, Bae S, Hong J, et al. Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis. Proc Natl Acad Sci USA 2010; 107:21082-21086.
45. Park MH, Song MJ, Cho MC, et al. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology 2012; 135:63-72.
46. Paya CV, Kenmotsu N, Schoon RA, Leibson PJ. Tumor necrosis factor and lymphotoxin secretion by human natural killer cells leads to antiviral cytotoxicity. J Immunol 1988; 141:1989-1995.
47. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995; 181:1235-1238.
48. Carbone E, Ruggiero G, Terrazzano G, et al. A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction. J Exp Med 1997; 185:2053-2060.
49. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998; 188:2375-2380.